| 产品描述: | Tivumecirnon (FLX475) is an orally active, selective CCR4 antagonist. Tivumecirnon blocks the binding of CCR4 to its ligands, CCL17 and CCL22, thereby reducing Treg infiltration into the tumor microenvironment. Tivumecirnon has antitumor activity[1][2][3][4]. |
| 靶点: |
CCR4 |
| 体内研究: |
Tivumecirnon 与 Pembrolizumab 联合使用,可用于非小细胞肺癌的治疗研究[1]。 |
| 参考文献: |
1. Tae Min Kim, et al. 629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor[J]. 2023. 2. Hilary Plake BECK, et al. Chemokine receptor modulators and uses thereof. WO2018022992. 3. Adam Grant, et al. Abstract 2485: A combined mregDC and Treg signature associates with antitumor efficacy of CCR4 antagonist tivumecirnon FLX475. Cancer Res 15 March 2024; 84 (6_Supplement): 2485. 4. Dirk G. Brockstedt, et al., Clinical and biological activity of FLX475, an oral CCR4 antagonist, in advanced cancer. Journal of Clinical Oncology. 2023. 41, 2625-2625. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.84 ml |
9.201 ml |
18.402 ml |
| 5 mM |
0.368 ml |
1.84 ml |
3.68 ml |
| 10 mM |
0.184 ml |
0.92 ml |
1.84 ml |
| 50 mM |
0.037 ml |
0.184 ml |
0.368 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |